3:00 AM
Nov 15, 2018
 |  BC Extra  |  Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA).

Cadent formed via last year's merger between Luc Therapeutics Inc. and Ataxion Inc., gaining lead product, CAD-1883, from the latter. The positive allosteric modulator of potassium channel KCa2.2 (KCNN2) and KCNN3 is in Phase I testing.


Read the full 338 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >